ReviewAnnals of medicine2025
Targeting high endothelial venules: potential strategies for cancer treatment.
Review in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh endothelial venules (HEVs) are specialized blood vessels found primarily in lymphoid tissues, notably at the cortico-paracortical junction of lymph nodes (LNs). They play a key role in lymphocyte trafficking, facilitating the entry of lymphocytes into peripheral lymphoid organs.
objectiveRecent evidence indicates the presence of HEVs within tumor tissues, where they form part of tertiary lymphoid structures. This review aims to explore the structural and functional alterations of HEVs in tumors and LNs, and investigate their role in cancer prognosis and response to immunotherapy.
methodsWe conducted a comprehensive review of recent studies examining HEVs in tumors and LNs, with a focus on their involvement in immune responses and cancer progression. Additionally, the use of MECA-79 as a specific HEV marker was considered as a potential therapeutic target.
resultsHEVs within tumors have been associated with improved immune surveillance and better prognosis in certain cancers. The presence of HEVs in tumors correlates with enhanced immune cell infiltration and may influence the effectiveness of immunotherapy treatments. Targeting HEVs, particularly through MECA-79, holds promise as a novel therapeutic strategy to modulate tumor immunity.
conclusionTargeting HEVs in tumor tissues represents a promising avenue for cancer therapy. Further research is needed to optimize strategies for modulating HEV function and to better understand their role in immune responses to cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.